Trupanion (NASDAQ:TRUP) released its quarterly earnings results on Thursday. The financial services provider reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01, Fidelity Earnings reports. Trupanion had a negative net margin of 0.75% and a negative return on equity of 2.08%. The company had revenue of $105.48 million during the quarter, compared to the consensus estimate of $104.92 million.
Shares of NASDAQ TRUP traded down $6.87 during midday trading on Friday, reaching $29.40. 2,005,249 shares of the company were exchanged, compared to its average volume of 329,537. The stock’s 50-day moving average price is $33.90 and its 200-day moving average price is $29.72. The stock has a market cap of $1.19 billion, a P/E ratio of -326.67 and a beta of 1.76. Trupanion has a one year low of $20.84 and a one year high of $38.06. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.17.
In related news, Director Murray B. Low sold 3,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $34.21, for a total value of $102,630.00. Following the sale, the director now owns 179,942 shares of the company’s stock, valued at $6,155,815.82. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Darryl Rawlings sold 4,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $33.22, for a total transaction of $132,880.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,300 shares of company stock worth $1,007,207. Insiders own 13.61% of the company’s stock.
A number of research firms have recently weighed in on TRUP. Stifel Nicolaus downgraded shares of Trupanion from a “buy” rating to a “hold” rating and lifted their price target for the company from $32.00 to $38.00 in a research report on Wednesday, January 8th. BidaskClub upgraded shares of Trupanion from a “hold” rating to a “buy” rating in a research report on Saturday, January 25th. Northland Securities reiterated a “buy” rating and issued a $40.00 price target on shares of Trupanion in a research report on Wednesday, November 6th. TheStreet upgraded shares of Trupanion from a “d+” rating to a “c-” rating in a research report on Tuesday, November 26th. Finally, Raymond James cut shares of Trupanion from an “outperform” rating to a “market perform” rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $36.00.
Trupanion Company Profile
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.